OBTAINING HIV-RESISTANT T-CELLS Russian patent published in 2024 - IPC C12N15/867 

FIELD: molecular biology; virology; biomedicine.

SUBSTANCE: invention relates to cell technologies. Described is a construct for producing HIV-resistant human CD4⁺ lymphocytes, which is the same or different two sequences of a peptide from the C-terminal heptad repeat of the viral protein gp41, separated by a sequence for separate translation of P2A SEQ ID No. 4, wherein said sequences are located between the CD52 protein export signal SEQ ID No. 5 and the GPI-anchoring signal of the CD52 protein SEQ ID No. 6. Invention extends the range of products for HIV-1 therapy. Also described is a recombinant bicistronic lentiviral vector for producing HIV-resistant T-cells, coding construct according to claims 1, 2, located under a single promoter, constructed on the basis of commercial lentivector vector pCDH-CMV-MCS-EF1-copGFP. Method for producing HIV-resistant human CD4⁺ lymphocytes, involving the following steps: lentivirus accumulations in HEK293T cells after transfection with lentiviral vectors of the third generation, including the vector according to the invention; filtration; addition of the accumulated third generation lentivirus to the T-cell line CEM/R5 or primary human CD4⁺ lymphocytes; integration of the declared structure into the genome of the target cell; sorting of cells in 48 hours by presence of peptide by means of immunofluorescent staining.

EFFECT: invention extends the range of products for treating HIV.

7 cl, 5 dwg, 2 ex